Comparation of CAR T19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma

Caixia Li,Ying Zhang,Changfeng Zhang,Jia Chen,Xiaoyan Lou,Xiaochen Chen,Liqing Kang,Nan Xu,Minghao Li,Jingwen Tan,Xiuli Sun,Jin Zhou,Zhen Yang,Xiangping Zong,Pu Wang,Ting Xu,Changju Qu,Haiwen Huang,Zhengming Jin,Lei Yu,Depei Wu

Comparation of CAR T19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma

2019

BACKGROUND Autologous stem cell transplantation (ASCT) is the standard treatment for refractory/relapsed B cell non-Hodgkin’s lymphoma (R/R B-NHL), whereas chimeric antigen receptor T (CAR-T) therapy targeting CD19 is emerging as an alternative strategy. Here, we report a comparative analysis of the 2 strategies in a single center.

Keywords:

Autologous stem-cell transplantation
Oncology
Refractory
Relapsed Non-Hodgkin's Lymphoma
Internal medicine
Medicine
Single Center
Gastroenterology
Standard treatment
Cytokine release syndrome
Adverse effect
Cytopenia
Transplantation
Hematology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations